InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
42 hedge funds and large institutions have $29.4M invested in InVivo Therapeutics Holdings Corp in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 7 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less capital invested
Capital invested by funds: $32.9M → $29.4M (-$3.55M)
18% less funds holding
Funds holding: 51 → 42 (-9)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
75% less call options, than puts
Call options by funds: $42K | Put options by funds: $170K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.4M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$162K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$162K |
| 4 |
State Street
Boston,
Massachusetts
|
+$162K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$80.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WF
Welch & Forbes
Boston,
Massachusetts
|
-$889K |
| 2 |
Millennium Management
New York
|
-$566K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$379K |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$242K |
| 5 |
Citigroup
New York
|
-$162K |
NVIV Hedge Fund Activity: Q1 2017 in Review
42 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q1 2017, worth a combined $29.4M — down 11% from $32.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NVIV and 2 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was BlackRock, opening a new position worth an estimated $8.4M. The largest seller was Welch & Forbes, cutting an estimated $889K.
- 42 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q1 2017, down from 51 in Q4 2016.
- Funds reported $29.4M of InVivo Therapeutics Holdings Corp stock for Q1 2017, down 11% quarter-over-quarter.
- 2 funds opened new InVivo Therapeutics Holdings Corp positions in Q1 2017 and 7 closed out, a net change of -5 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q1 2017 was BlackRock, an estimated $8.4M added.
- The largest InVivo Therapeutics Holdings Corp seller in Q1 2017 was Welch & Forbes, an estimated $889K sold.
Based on aggregated 13F filings for Q1 2017.